Patents by Inventor Kin-Hing William Lau
Kin-Hing William Lau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210177908Abstract: In one aspect, anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided. In some embodiments, the anabolic agent fusion protein comprises a platelet derived growth factor (PDGF) or a fibroblast growth factor (FGF) and an Asp-Ser-Ser tripeptide (DSS) repeat sequence. In another aspect, methods of promoting bone growth and methods of treating a fracture using anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided.Type: ApplicationFiled: June 28, 2019Publication date: June 17, 2021Inventors: Zhang XIAOBING, David BAYLINK, Wanqui CHEN, Kin-Hing William LAU
-
Patent number: 9850499Abstract: A vector for generating induced pluripotent stem cells from human target cells comprising a) a vector backbone, b) exactly two, three or four transcription and reprogramming factor genes, each gene separated by a 2a self-cleavage peptide sequence, c) a spleen focus-forming virus promoter, and d) a post-transcriptional regulatory element Wpre, with or without an anti-apoptotic factor gene. A method for generating integration-free induced pluripotent stem cells, the method comprising: a) providing target cells, b) providing one or more than one vector according to the present invention, c) transducing or transfecting the target cells with the one or more than one vector, and d) culturing the transduced or transfected cells in a cell culture, thereby generating integration-free induced pluripotent stem cells.Type: GrantFiled: September 9, 2016Date of Patent: December 26, 2017Assignee: Loma Linda UniversityInventors: David J. Baylink, Kin-Hing William Lau, Xiaobing Zhang
-
Patent number: 9789162Abstract: Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB.Type: GrantFiled: November 4, 2015Date of Patent: October 17, 2017Assignees: The United States of America as represented by the Department of Veteran Affairs, Loma Linda UniversityInventors: David Baylink, Kin-Hing William Lau, Wanqiu Chen, Xiao-Bing Zhang
-
Publication number: 20170009252Abstract: A vector for generating induced pluripotent stem cells from human target cells comprising a) a vector backbone, b) exactly two, three or four transcription and reprogramming factor genes, each gene separated by a 2a self-cleavage peptide sequence, c) a spleen focus-forming virus promoter, and d) a post-transcriptional regulatory element Wpre, with or without an anti-apoptotic factor gene. A method for generating integration-free induced pluripotent stem cells, the method comprising: a) providing target cells, b) providing one or more than one vector according to the present invention, c) transducing or transfecting the target cells with the one or more than one vector, and d) culturing the transduced or transfected cells in a cell culture, thereby generating integration-free induced pluripotent stem cells.Type: ApplicationFiled: September 9, 2016Publication date: January 12, 2017Inventors: David J. Baylink, Kin-Hing William Lau, Xiaobing Zhang
-
Patent number: 9458215Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: GrantFiled: May 27, 2014Date of Patent: October 4, 2016Assignees: Loma Linda University, The United States of America as represented by the Department of Veteran AffairsInventors: Kin-Hing William Lau, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan, David J. Baylink
-
Publication number: 20160120944Abstract: Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB.Type: ApplicationFiled: November 4, 2015Publication date: May 5, 2016Applicants: The United States Government as represented by the Department of Veterans Affairs, Loma Linda UniversityInventors: David Baylink, Kin-Hing William Lau, Wanqiu Chen, Xiao-Bing Zhang
-
Publication number: 20150335662Abstract: A method for treating a patient with an episode of sepsis. A method for categorizing the severity of an episode of sepsis in a patient.Type: ApplicationFiled: January 17, 2014Publication date: November 26, 2015Inventors: Hung Bryant Nguyen, David J. Baylink, Kin-Hing William Lau
-
Publication number: 20150240219Abstract: Vectors, such as retroviral vectors and transposon-based nonviral vectors, are disclosed herein that can be used to target transgene expression to the proliferating periosteal cells and cells in the marrow space after bone fracture. In one embodiment, these vectors include a human Cox-2 gene that is modified to improve mRNA stability and protein translation by truncating the 3? untranslated region (UTR). In addition, in some embodiments, the native translation signal is replaced with an optimized Kozak sequence. These vectors can be used alone or with vectors expressing BMP2/4, FGF-2, or LMP-1 gene to repair bone fractures and increase prostaglandin secretion. Methods for identifying agents that accelerate bone repair are also disclosed.Type: ApplicationFiled: April 15, 2015Publication date: August 27, 2015Inventors: David Baylink, Kin-Hing William Lau, Charles Rundle, Donna Strong, Shin-Tai Chen, Thomas Linkhart
-
Publication number: 20140256917Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: ApplicationFiled: May 27, 2014Publication date: September 11, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, Loma Linda UniversityInventors: Kin-Hing William Lau, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan, David J. Baylink
-
Publication number: 20140220677Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: ApplicationFiled: April 4, 2014Publication date: August 7, 2014Applicant: LOMA LINDA UNIVERSITYInventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
-
Patent number: 8772571Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: GrantFiled: September 10, 2010Date of Patent: July 8, 2014Assignees: The United States of America as represented by the Department of Veterans Affairs, Loma Linda UniversityInventors: Kin-Hing William Lau, David J. Baylink, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan
-
Publication number: 20140141005Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: ApplicationFiled: January 24, 2014Publication date: May 22, 2014Applicant: LOMA LINDA UNIVERSITYInventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
-
Publication number: 20140134143Abstract: A vector for generating induced pluripotent stem cells from human target cells comprising a) a vector backbone, b) exactly two, three or four transcription and reprogramming factor genes, each gene separated by a 2a self-cleavage peptide sequence, c) a spleen focus-forming virus promoter, and d) a post-transcriptional regulatory element Wpre, with or without an anti-apoptotic factor gene. A method for generating integration-free induced pluripotent stem cells, the method comprising: a) providing target cells, b) providing one or more than one vector according to the present invention, c) transducing or transfecting the target cells with the one or more than one vector, and d) culturing the transduced or transfected cells in a cell culture, thereby generating integration-free induced pluripotent stem cells.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicant: Loma Linda UniversityInventors: David J. Baylink, Kin-Hing William Lau, Xiaobing Zhang
-
Patent number: 8722399Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: GrantFiled: January 24, 2014Date of Patent: May 13, 2014Assignee: Loma Linda UniversityInventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
-
Patent number: 8669104Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: GrantFiled: November 8, 2013Date of Patent: March 11, 2014Assignee: Loma Linda UniversityInventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
-
Publication number: 20140065157Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: LOMA LINDA UNIVERSITYInventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
-
Patent number: 8647616Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: GrantFiled: February 13, 2013Date of Patent: February 11, 2014Assignee: Loma Linda UniversityInventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
-
Publication number: 20130209477Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.Type: ApplicationFiled: February 13, 2013Publication date: August 15, 2013Inventors: David J. BAYLINK, Kin-Hing William LAU, Xuezhong QIN
-
Publication number: 20110004947Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: ApplicationFiled: September 10, 2010Publication date: January 6, 2011Inventors: Kin-Hing William Lau, David J. Baylink, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan
-
Patent number: 7816140Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: GrantFiled: June 13, 2006Date of Patent: October 19, 2010Assignee: The United States of America as represented by the Department of Veterans AffairsInventors: Kin-Hing William Lau, David J. Baylink, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan